Summary
This 8-K filing from Pfizer Inc. (PFE) dated September 1, 2000, primarily serves to incorporate previously filed restated financial information related to the completed merger with Warner-Lambert Company on June 19, 2000. Investors should note that this report makes available audited consolidated financial statements for fiscal years ending December 31, 1999, 1998, and 1997, along with unaudited interim financial statements for the first quarter of 2000 and the comparable period in 1999. This filing provides updated financial data necessary for a comprehensive understanding of Pfizer's financial position and performance post-merger.
Key Highlights
- 1Pfizer completed its merger with Warner-Lambert Company on June 19, 2000, making Warner-Lambert a wholly owned subsidiary.
- 2The filing incorporates restated audited consolidated financial statements for the years ended December 31, 1999, 1998, and 1997.
- 3Restated audited consolidated statements of income, shareholders' equity, and cash flows for the three years ended December 31, 1999, are included.
- 4Unaudited condensed consolidated financial statements as of April 2, 2000, and for the three-month periods ended April 2, 2000, and April 4, 1999, are also filed.
- 5This report includes Management's Discussion and Analysis of Financial Condition and Results of Operations for the relevant periods.
- 6Consents from independent accountants KPMG LLP and PricewaterhouseCoopers LLP are included.
- 7Financial Data Schedules for fiscal years 1999, 1998, and 1997 are provided.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially incorporate by reference previously filed restated audited and unaudited financial information related to Pfizer's merger with Warner-Lambert Company, which was completed on June 19, 2000.
The filing includes restated audited consolidated balance sheets for December 31, 1999 and 1998, and restated audited consolidated statements of income, shareholders' equity, and cash flows for the years ended December 31, 1999, 1998, and 1997. It also includes restated unaudited condensed consolidated financial statements for April 2, 2000, and the three-month periods ended April 2, 2000, and April 4, 1999.
No, this filing primarily incorporates already released restated financial information. It does not present new, unreleased financial results or performance data but rather consolidates and makes readily accessible the updated financial statements and related analysis resulting from the Warner-Lambert merger.
The filing includes consents from Pfizer's independent accountants, KPMG LLP, and also from PricewaterhouseCoopers LLP, indicating their involvement in reviewing and attesting to the restated financial information.